Telix Pharmaceuticals: Request for listing of securities – TLX

0

Quotation request for +securities

Summary of the announcement

Name of entity

TELIX PHARMACEUTICALS LIMITED

Type of news

New announcement

Date of this announcement

Monday, January 31, 2022

The +securities to be listed are:

+Securities issued as part of one or more transactions previously announced to the market in an Appendix 3B

Total number of +stocks to be listed

ASX + security

Number of +titles to

coded

Security description

be quoted

Date of issue

TLX

REGULAR FULLY PAID

519 481

01/31/2022

See next page for full listing details

Quotation request for +securities

1 / 6

Quotation request for +securities

Part 1 – Entity and listing details

1.1 Entity name

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) request +listing of the following +securities and accept the questions set out in Appendix 2A of the ASX Listing Rules.

1.2

Registered number type

Registration number

ACN

616620369

1.3

ASX issuer code

TLX

  1. The ad is New announcement
  2. Date of this announcement

31/1/2022

Quotation request for +securities

2 / 6

Quotation request for +securities

Part 2 – Type of problem

2.1 The securities to be listed are:

+Securities issued as part of one or more transactions previously announced to the market in an Appendix 3B

Details of previous Annex 3B:

Announcement date and

Ad Title

Selection of Annex 3B to submit a quote

Time

request

24-Jan-2022 09:00

New – Proposed issue of securities –

A location or other type of problem

TLX

2.3a.2 Are there other issuances of +securities still to take place to carry out the transaction(s) referred to in appendix 3B?

Yes

2.3a.3 Please provide details of other issues of securities + that have not yet taken place to complete the transaction(s) referred to in Annex 3B

The Company is seeking the listing of 519,481 shares which have been settled as of January 31, 2022. The Company will seek a separate listing for the balance of 160,519 shares to be issued under the Placement.

Quotation request for +securities

3 / 6

Quotation request for +securities

Part 3A – number and type of securities + to be quoted when the issue has already been notified to the ASX in an annex 3B

Investment Details

alone

ASX + security code and description

TLX: REGULAR FULLY PAID

Date of issue

31/1/2022

use

Release Schedule

Provide a schedule for the distribution of new +titles according to the categories defined in the left column –

including the number of beneficiaries and the total percentage of new+securities held by beneficiaries in each

Category.

personalfor

Total percentage of +shares held

Number of +shares held

Number of holders

For example, to enter a value of 50%

please enter 50.00

1 – 1000

%

1,001

– 5,000

%

5,001

– 10,000

%

10,001 – 100,000

%

100,001 and more

%

Quotation request for +securities

4 / 6

Quotation request for +securities

Problem details

Number of +securities to be listed

519 481

Are the +securities issued for cash consideration?

Yes

In what currency is the cash consideration paid? What is the issue price per +share?

AUD – Australian Dollar

AU$7,700,000

Any other information that the entity wishes to provide on the +securities to be listed

Quotation request for +securities

5 / 6

This is an excerpt from the original content. To continue reading it, go to the original document here.

Warning

Telix Pharmaceuticals Ltd. published this content on January 30, 2022 and is solely responsible for the information contained therein. Distributed by public, unedited and unmodified, on January 30, 2022 21:40:09 UTC.

Public now 2022

All the news from TELIX PHARMACEUTICALS LIMITED
Sales 2021 8.19M
5.73 million
5.73 million
Net income 2021 -50.9M
-35.6M
-35.6M
Net cash 2021 83.5 million
58.4M
58.4M
PER 2021 ratio -34.2x
2021 performance
Capitalization 1,916 million
1,340 million
1,339 million
EV / Sales 2021 224x
EV / Sales 2022 20.6x
# of employees
Floating

Chart TELIX PHARMACEUTICALS LIMITED
Duration :

Period :

Telix Pharmaceuticals Limited Technical Analysis Chart |  MarketScreener

Technical Analysis Trends TELIX PHARMACEUTICALS LIMITED

Short term Middle term Long term
Tendencies Bearish Neutral Bullish

Evolution of the income statement

To sell

To buy

Medium consensus TO BUY
Number of analysts 5
Last closing price

$6.24

Average target price

$8.86

Average Spread / Target 42.0%
Share.

Comments are closed.